Highlights Inhibikase Therapeutics, Inc.

Equities

IKT

US45719W2052

Market Closed - Nasdaq Other stock markets 02:00:01 29/06/2024 am IST			5-day change	1st Jan Change
1.21 ^USD	-11.68%		-13.57%	-4.72%

17/06	Inhibikase Therapeutics Completes Enrollment of the Phase 2 ?201? Trial Evaluating Risvodetinib in Untreated Parkinson?s Disease	CI
05/06	Inhibikase Therapeutics, Inc. Announces Expansion to Its Therapeutic Pipeline	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Inhibikase Therapeutics Completes Enrollment of the Phase 2 ?201? Trial Evaluating Risvodetinib in Untreated Parkinson?s Disease	17/06	CI
Inhibikase Therapeutics, Inc. Announces Expansion to Its Therapeutic Pipeline	05/06	CI
Inhibikase Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	16/05	CI
Inhibikase Therapeutics Announces Final Pre-Ind Meeting Outcomes for Ikt-001Pro as A Treatment for Pulmonary Arterial Hypertension	09/05	CI
Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension	03/04	CI
Earnings Flash (IKT) INHIBIKASE THERAPEUTICS Posts 2023 Revenue $260,501	28/03	MT
Inhibikase Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03	CI
Inhibikase Therapeutics to Provide Trial Update for Risvodetinib At the 2024 International Conference Onzheimer's and Parkinson's Diseases and Related Neurological Disorders	07/03	CI
Inhibikase Therapeutics Announces Preliminary Outcomes of Its Pre-Nda Meeting with the Fda on the Pathway for Approval for Ikt-001Pro in Blood and Gastrointestinal Cancers	07/02	CI
Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib	29/01	CI
Inhibikase Therapeutics, Inc. Provides Update on Development Programs	19/12	CI
Inhibikase Therapeutics, Inc. Granted Pre-NDA Meeting with the FDA for IkT-001Pro	04/12	CI
Earnings Flash (IKT) INHIBIKASE THERAPEUTICS Reports Q3 Revenue $79.6M	15/11	MT
Inhibikase Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	15/11	CI
Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson?s Disease and Provides Update on Ongoing Enrollment	16/23/16	CI
Inhibikase Therapeutics, Inc. Announces Development of Novel Formulation of Rampsvodetinib	24/23/24	CI
Inhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of Ikt-001Pro	17/23/17	CI
Earnings Flash (IKT) INHIBIKASE THERAPEUTICS Posts Q2 Revenue $116.4M	15/23/15	MT
Inhibikase Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/23/15	CI
Inhibikase Therapeutics to Implement 1-for-6 Reverse Stock Split	29/23/29	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Inhibikase Therapeutics, Inc.

Equities

IKT

US45719W2052

Highlights

Filters